التفاصيل البيبلوغرافية
| العنوان: |
Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies |
| المؤلفون: |
Bazinet, M., Anderson, M., Pântea, V.E., Plăcintă, G.P., Moscalu, I.D., Москалу, Ю., Cebotarescu, V.T., Cojuhari, L.B., Jimbei, P., Iarovoi, L.P., Smeşnoi, V.I., Smeshnoi, V., Смешной, В., Musteaţă, T., Jucov, A.I., Jucov, A., Gersch, J., Holzmayer, V., Kuhns, M., Cloherty, G., Vaillant, A. |
| المصدر: |
Journal of Hepatology 142-142 |
| سنة النشر: |
2020 |
| الوصف: |
Background and aims: After completion of NAP-based combination therapy with pegIFN and follow-up in the REP 301-LTF study 3.5 years and REP 401 study 48 weeks, combined HBV outcomes were functional cure HBsAg 0.05 IU/mL, HBV DNA target not detected, normal ALT [FC] in 18/52 35%, virologic control HBV DNA le;2000 IU/mL, normal ALT [VC] in 19/52 36% and rebound R in 15/52 29% of participants. The goal of this study was to analyze the relationship between HBV outcome and experimental virologic markers of HBV infection. Methods: Frozen serum samples n = 1153 from all 52 participants in the REP 301/REP 301-LTF and REP 401 studies were analyzed by the following: 1. Abbott ARCHITECT HBsAg NEXT analytical sensitivity 0.005 IU/ mL. 2. Abbott research use only RUO assays for HBsAg isoforms large, medium, small. 3. Abbott RUO assay for HBsAg/anti-HBs immune complexes HBsAg IC. 4. Abbott RUO assay for pregenomic HBV RNA pgRNA. 5. Fujirebio HBcrAg LLOQ 3log10 U/mL. Results: All participants experiencing HBsAg loss 0.05 IU/mL during therapy 28/52 rapidly became negative with HBsAg Next. HBsAg 0.005 IU/mL was confirmed at the end of follow-up in 18/18 functional cure and 1/1 virologic control participants with previous HBsAg 0.05 IU/mL. A more rapid reduction of S-HBsAg relative to the reduction of other HBsAg isoforms occurred in 39/40 participants with HBsAg decline 2 log10 from baseline, consistent with targeting SVPs. At the end of follow-up, HBsAg isoforms were detectable in 0/18 FC, 17/19 VC and 15/15 R participants. HBsAg IC relative luminescence units or RLU were in the positive range in 30/52 participants at baseline and at the end of follow-up in 0/18 FC, 5/19 VC and 10/15 R participants. At baseline, HBV RNA and HBcrAg were present in 42 and 34 participants. HBV RNA loss on therapy occurred in 5/ 14 FC, 5/16 VC and 1/12 R participants. HBcrAg LLOQ on therapy occurred in 5/9 FC, 7/15 VC and 3/10 R participants. At the end of follow-up, both HBV RNA and HBcrAg were LLOQ in 1/18 FC, 15/19 VC and 13/15 R participants. ... |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| تدمد: |
01688278 |
| Relation: |
https://ibn.idsi.md/vizualizare_articol/201380; urn:issn:01688278 |
| الاتاحة: |
https://ibn.idsi.md/vizualizare_articol/201380 |
| Rights: |
info:eu-repo/semantics/openAccess |
| رقم الانضمام: |
edsbas.D0F6F140 |
| قاعدة البيانات: |
BASE |